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Abstract
Background: Patients with acute coronary syndrome (ACS) in India have increased pre-hospital delay and low
rates of thrombolytic reperfusion. Use of ECG could reduce pre-hospital delay among patients who first present to
a general practitioner (GP). We assessed whether performing ECG on patients with acute chest pain would
improve long-term outcomes and be cost-effective.
Methods: We created a Markov model of urban Indian patients presenting to a GP with acute chest pain to
compare a GP’s performing an ECG versus not performing one. Variables describing the accuracy of a GP’s referral
decision in chest pain and ACS, ACS treatment patterns, the effectiveness of thrombolytic reperfusion, and costs
were derived from Indian data where available and other developed world studies. The model was used to
estimate the incremental cost-effectiveness ratio (ICER) of the intervention in 2007 US dollars per quality adjusted
life years (QALY) gained.
Results: Under baseline assumptions, the ECG strategy cost an additional $12.65 per QALY gained compared to no
ECG. Sensitivity analyses around the cost of the ECG, cost of thrombolytic, and referral accuracy of the GP yielded
ICERs for the ECG strategy ranging between cost-saving and $1124/QALY. All results indicated the intervention is
cost-effective under current World Health Organization recommendations.
Conclusions: While direct presentation to the hospital with acute chest pain is preferable, in urban Indian patients
presenting first to a GP, an ECG performed by the GP is a cost-effective strategy to reduce disability and mortality.
This strategy should be clinically studied and considered until improved emergency transport services are available.
Background
Ischemic heart disease is already the leading cause of
mortality in India [1], and the magnitude of this dis-
ease’s impact is expected to grow over the next two dec-
ades [2]. It is projected that ischemic heart disease will
result in two and one-half million Indian deaths by 2020
[3]. Acute coronary syndrome (ACS), including both
ST-elevation myocardial infarction (STEMI) and non-ST
elevation ACS (NSTE-ACS), is an important manifesta-
tion of ischemic heart disease. Rapid diagnosis and
treatment with appropriate reperfusion therapies has
been proven to increase survival for patients with
STEMI. This benefit of reperfusion diminishes as the
interval from time of symptom onset to initiation of
therapy increases [4]. Current ACS guidelines emphasize
the importance of rapid hospital care, especially for
STEMI patients who may be eligible for thrombolytic
reperfusion within the first twelve hours [4,5].
A recent multi-center Indian registry found only a
mean of 58.5% of Indian STEMI patients received
thrombolytics, (6% of eligible patients undergo percuta-
neous revascularization) with an average interval
between symptom onset and hospital arrival (pre-hospi-
tal delay) of five hours [6]. This was twice as long as the
median delay seen in the second Euro Heart survey [7].
Increased pre-hospital delay in India has been attributed
to poor patient knowledge about ACS, lack of emer-
gency medical services (EMS) infrastructure, and trans-
portation difficulties [1,6,8,9].
In developed countries, pre-hospital electrocardiogra-
phy (ECG) performed by EMS technicians is associated
with faster access to reperfusion therapies for STEMI
patients [10]. As urban EMS systems are often lacking
in India, ACS patients have been reported as likely to
first present to a general practitioner (GP), which has
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delay [8,9]. However, one retrospective Indian study of
hospitalized ACS patients observed that although overall
pre-hospital presentation to a GP doubled the risk of
significant pre-hospital delay [8], a subgroup in which
the GP performed an electrocardiogram (ECG) had
reduced delay compared to patients who did not have
an ECG and even to those who presented to the hospital
directly. This finding was attributed to improved diagno-
sis of ACS and more prompt referral of patients to a
hospital (unpublished data - with permission from Dr.
Rajagopalan 5/25/08). These data were obtained under
current urban transportation conditions.
It is therefore plausible that a pre-hospital ECG per-
formed by a GP will have an analogous effect in increas-
ing timely access to reperfusion through quicker and
more accurate referral to a hospital. Such a strategy
could be useful until improvements are made to India’s
EMS infrastructure. We modeled the hypothesis that
compared to an urban GP not performing an ECG, a
GP performing one leads to decreased pre-hospital
delay, and consequentially increased eligibility for
thrombolytics and improved long-term outcomes. Sub-
sequently, we assessed the cost-effectiveness of this ECG
strategy compared to not performing one.
Methods
Decision-Analytic Model
We developed a Markov model of urban Indian adult
patients presenting to a general practitioner with acute
chest pain to assess the overall benefits and costs of the
GP performing an ECG versus not performing one (Fig-
ure 1). Based on a 2% incidence rate of chest pain this
represents about 8 million patients per year in urban
areas in India. The model essentially outlined the survi-
val of patients presenting with chest pain. One influence
on survival was receiving appropriate thrombolytics for
patients with STEMI. This was improved by both
increasing the number of correct referrals from the GP
and reducing the delay in presentation to a hospital
where thrombolytics could be administered. Another
influence on improved mortality was modeled for those
with NSTE-ACS who are appropriately admitted to the
hospital. Costs were also limited by correct referrals. In
the ECG arm of the model, we evaluated the referral
decision made by GPs based on clinical history, physical
examination, and the ECG. In the other arm, the GP’s
decision was modeled as based on history and physical
examination alone. The cohort was modeled until death,
either from cardiovascular disease or from other causes
with repeated annual cycles. Updates in risk each year
were based on age, ACS history and life-tables for India.
Costs and quality adjusted survival were calculated
based on estimates derived from prior studies of a GP’s
accuracy in referring patients with chest pain to either
an appropriate medical facility or home. In both arms,
we modeled that STEMI patients incorrectly sent home
(false negatives) would be delayed in presenting to a
hospital, and consequently would be ineligible for
thrombolytic treatment. Patients incorrectly referred to
a hospital without ACS (false positives) would incur
costs of further medical evaluation. We modeled a
cohort of adult patients with the median age of sixty
years old, which is the median age of ACS in India [6].
In order to model the clinical effect of the GP per-
forming an ECG, we treated the GP’s referral decision
as a diagnostic test (Table 1). Sensitivity was the fraction
of total patients with ACS who were correctly referred,
while specificity was the fraction of total patients with-
out ACS who were correctly sent home by the GP. The
baseline sensitivities were derived from published evi-
dence [11-16] with minor adjustments from the Indian
observations of Rajagopalan and colleagues (unpublished
data).
Specificity of the GP’s referral decision was derived
from studies performed in developed countries, as no
Indian data were available. The specificity of the referral
decision when an ECG was administered was estimated
from the approximate mean specificity of admission
decisions for patients with acute chest pain in the emer-
gency department [12-16]. The specificity of the deci-
sion without an ECG was lower owing to decreased
diagnostic certainty based on a study of physicians diag-
nosing acute myocardial infarction without the use of an
ECG [17]. We modeled among patients without ACS
incorrectly referred to the hospital by the GP (false posi-
tives), a fraction equal to one minus the specificity of
GP with the ECG would be admitted for 24 hours to
“rule-out” ACS.
We adhered to recommendations of the US Panel on
Cost-Effectiveness in Health and Medicine in choosing a
societal perspective for the baseline analysis [18]. The
entire chest pain cohort was modeled until death, either
from cardiovascular disease or other causes. No ethics
approval was required, because no patients were used
for data collection. All analyses were performed with
TreeAge Pro Suite 2008 (TreeAge Software Inc., Wil-
liamstown, MA). All authors had full access to all the
data and had final responsibility for the decision to sub-
mit for publication.
Chest Pain and ACS Data
ACS is the diagnosis in 10-20% of acute chest pain
patients in developed world studies [19-22]. This per-
centage is unknown in India, so we elected to use the
lower bound of 10% for our baseline analysis. This deci-
sion was based on the knowledge that the overall preva-
lence of coronary disease is likely lower and the
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tuberculosis) likely greater compared to developed coun-
tries. However, we tested the entire range of values in
the sensitivity analysis. Based on the recent CREATE
registry, which is the largest reported source of ACS
data specific to urban India, we modeled 60.6% as hav-
ing STEMI and the remainder having NSTE-ACS [6].
The model assumed that 58.5% of patients with
STEMI correctly referred by the GP received thromboly-
tics, which is the Indian average [6]. As Rajagopalan and
colleagues observed a median delay of 24 hours for ACS
patients who were misdiagnosed by a GP (unpublished
data), we modeled that none of the STEMI patients
incorrectly sent home by the GP received thrombolytics
regardless of eventual hospitalization status. The short-
and long-term effectiveness and risks of thrombolytics
were derived from the overall effects reported in the
Second International Study of Infarct Survival (ISIS-2)
and Fibrinolytic Therapy Trialists (FTT) studies [23-25].
All patients who were treated in a hospital received
early aspirin therapy, which had a relative risk reduction
derived from ISIS-2.
Mortality to 35 days was estimated from ISIS-2 for
STEMI patients [23,24], and from the CREATE registry
for NSTE-ACS patients [6]. Patients with STEMI who
were incorrectly sent home by the GP but later returned
Figure 1 Markov model (simplified). “True positive,”“ false positive,”“ true negative,” and “false negative” describe the general practitioner’s
referral decision, and the values are based both on the reported test characteristics as well as the prevalence of acute coronary syndrome (ACS).
ASA = aspirin, NSTE-ACS = non ST-elevation acute coronary syndrome, STEMI = ST-elevation myocardial infarction.
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hospital delay conveying an additional 0.9% mortality,
which is half the first-day STEMI mortality rate in the
FTT and Clopidogrel and Metoprolol in Myocardial
Infarction (COMMIT) studies [25,26]. All ACS patients
who were incorrectly sent home by the GP and did not
return to the hospital had double the 35-day mortality
of those admitted, a hazard determined from developed
world studies of ACS patients incorrectly sent home
from the emergency department [11,21].
Mortality after 35 days for chest pain patients without
ACS was derived from World Health Organization
( W H O )l i f et a b l e sf o rI n d i a[ 2 7 ] .W ea s s u m e dt h a t
patients without ACS did not have ischemic heart dis-
ease, so we adjusted the annual mortality probabilities
to decrease the influence of heart disease for the first
ten years. In the patients who had ACS, for the first ten
years we used mortality and reinfarction data derived
from Law and colleagues [28], with adjustments for the
effects of secondary prevention. After ten years, the
annual mortality for ACS patients was equivalent to the
sum of fatal reinfarction and the yearly mortality in the
WHO life tables.
For secondary prevention after 35 days, we considered
a regimen of aspirin, a beta-blocker, a statin, and an
angiotensin converting enzyme (ACE) inhibitor. As an
international survey showed that the actual population
of patients taking secondary prevention in India is well
below those eligible [29], we modeled the relative risk
reduction of secondary prevention only for the
percentage of Indian patients taking the individual
drugs. The relative risk reductions of the secondary pre-
vention regimen were derived from the reported litera-
ture [30-33]. In accordance with evidence that has
suggested a diminishing effect of beta-blockers over
time [34], the beta-blocker was only included in the sec-
ondary prevention regimen for the first six years of the
model. We assumed that the relative risk reductions of
the drugs were independent, and therefore we calculated
the overall effect by multiplying the individual relative
risks associated with each drug.
Outcomes and Costs
Outcomes in the analyses were measured in quality
adjusted life-years (QALYs) gained and net health costs.
Q A L Y sw e r eo b t a i n e db yu s i n gt h ed i s a b i l i t yw e i g h t so f
the WHO Global Burden of Disease Project as used in
the 2nd edition of the Disease Control Priorities (DCP)
Project [35,36].
Costs of hospital admission, salaries, office visits, and
laboratory fees were derived from regional estimates
done for the Disease Control Priorities Project [37]. As
the median duration of hospitalization for ACS in India
is five days [6], we modeled a five day admission to a
secondary hospital with the pro-rated labor costs of a
cardiologist, junior doctor, nursing care, and an admin-
istrative worker. For patients who needed a blood trans-
fusion or stroke care owing to the adverse effects of
thrombolytics, additional days of hospitalization were
added. Drug costs were calculated from the
Table 1 Baseline values for input variables and costs
Baseline Value Source(s)
Input variables
Chest pain is caused by ACS 0.1 [19-22]
GP Sensitivity with ECG 0.818 Unpublished data from [8,11-16]
GP Sensitivity without ECG 0.667 Unpublished data from [8]
GP Specificity with ECG 0.5 [12-16]
GP Specificity without ECG 0.3 [17]
Correctly referred STEMI patients receiving thrombolysis (%) 58.5 [6]
Relative risk reduction of thrombolytics 0.750 [23,24]
Costs (2007 US$)
GP visit 1.76 [37]
ECG 1.93 [39,40,42-44]
Emergency department visit 3.48 [37]
Streptokinase 117.00 [38,45]
Admission 157.55 [37]
Blood transfusion 107.67 [37]
Stroke 211.37 [37]
Annual secondary prevention 16.56 [37,38]
ACS = acute coronary syndrome, ECG = electrocardiogram, GP = general practitioner, STEMI = ST-elevation myocardial infarction
Admission costs are for a 5-day admission. The cost of a blood transfusion includes an 3 additional days of hospitalization. The cost of a stroke includes
7 additional days of hospitalization. Annual secondary prevention includes two clinic visits and medications.
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costing data where available. All secondary prevention
drug costs were computed as a year’ss u p p l y ,t h o u g h
covering only the proportion of Indian patients taking
medical therapy as reported in the WHO-PREMISE
survey [29].
The baseline cost of an ECG was estimated as the cur-
rent reimbursement rate to private hospitals by India’s
Central Government Health Scheme (CGHS) in large
metropolitan areas [39]. An additional $0.08 cost was
added based on a 500 rupee training cost [40] spread
over an estimated 30 annual ECGs performed over a
five year period. We did not model the direct costs of
transportation to the hospital, time lost from work, or
rehabilitation. Initial costs obtained in India rupees prior
to 2007 were inflated to 2007 rupees using the Indian
wholesale price index [41] and then converted to 2007
US dollars with the midyear exchange rate. The costs
are modest but the Gross National Income (GNI) per
capita was approximately $800 in 2006, reflecting the
relatively cheap labor supply in India and as a result
lower costs.
All costs and benefits were tallied at mid-cycle incre-
ments. Those dying during a cycle were assumed to
incur one half of the utilities and costs of that cycle. All
costs as well as health outcomes were discounted at 3%
per year, which is consistent with guidelines [18]. Incre-
mental cost-effectiveness ratios (ICERs) were calculated
as the difference in costs between the ECG intervention
and no intervention divided by the increase in QALYs
gained.
Sensitivity Analysis
One-way sensitivity analyses on the “sensitivity” and
“specificity” of the GP’s referral decision relied on stu-
dies of admission decisions for emergency department
patients with acute chest pain [12-16]. Analyses of the
effectiveness of the thrombolytics relied on the standard
deviations reported in ISIS-2. As the efficacy of therapy
in real Indian settings may be substantially lower than
that in developed world controlled trials, we also
assessed reduction in thrombolytic efficacy of up to
50%. Sensitivity analyses of the costs of health-care
delivery relied on the ranges reported in the DCP work-
ing paper [37], except for the cost of an ECG which was
estimated from selected Indian price schedules as well
as one developed world reimbursement schedule for
comparison [42-44]. Analysis of the price of thromboly-
tic relied on a lower bound from an online Indian data-
base of drug prices [45] and an upper bound from the
International Drug Price Indicator Guide. In our sensi-
tivity analyses, we use the term “cost-saving” to mean
that the ECG intervention cost less and resulted in
more QALYs gained than not performing an ECG. We
also performed a probabilistic sensitivity analysis[46]
with second-order Monte Carlo simulation of 1000 ran-
domly selected sets of parameters in which we simulta-
neously sampled values from the distributions with
corresponding logit-means and logit-standard deviations.
Results
Under baseline assumptions, the strategy in which a GP
did not perform an ECG resulted in 12.423 QALYs
obtained over an average lifetime, while performing an
ECG resulted in 12.435 QALYs obtained (Table 2).
Approximately 57% of this gain in QALYs came from
the increased use of appropriate thrombolytics, 30%
from increased use of secondary prevention treatment
and the remaining 12% was related to improved hospital
survival for those appropriately referred as a result of
the ECG. The strategy of not performing an ECG cost
$50.37 per individual over the lifetime of the cohort,
while the ECG intervention cost $50.52 per individual.
Overall, the ECG intervention had an incremental cost-
effectiveness ratio (ICER) of $12.65 per QALY gained.
One-way sensitivity analyses around the “sensitivity”
and “specificity” of the GP’s referral decisions resulted
in ICERs that ranged between cost-saving to less than
$400/QALY (Table 3). The model was largely insensitive
to changes in the referral accuracy (sensitivity) of the
GP with an ECG, yielding ICERs from cost-saving to
$103/QALY. When the sensitivity of the GP without an
ECG was set to be equal to the baseline value of the GP
with the ECG, while holding the specificity constant, the
ECG intervention was cost-saving. When the same test
was performed for the specificity of the GP without an
ECG while holding the sensitivity constant, the ICER
was $351/QALY. If the sensitivity of the GP with ECG
was lower than the GP without an ECG then the no
ECG strategy could have a ICER of $580/QALY when
compared to the GP with ECG.
Sensitivity analysis around the prevalence of ACS
resulted in an ICER that ranged from cost-saving to
$119/QALY (Figure 2). If the ECG’sc o s tw a sm o d e l e d
as the maximum Indian cost of approximately $4, the
ICER of the ECG strategy was approximately $189/
Table 2 Results with baseline assumptions
Cost
(2007 US
$)
Effects
(QALYs
obtained)
ICER
($/QALY
gained)
GP without ECG 50.37 12.423
GP with ECG 50.52 12.435
Incremental
Change
0.15 0.012 12.65
ECG = electrocardiogram, GP = general practitioner, ICER = Incremental cost-
effectiveness ratio, QALY = quality adjusted life year
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cost in the United States [44], the ECG intervention
yielded an ICER of $1124/QALY. The threshold at
which the ICER for the cost of the ECG changed from
cost-saving to a positive value (cost more and gained
more QALYs) was approximately $2. Sensitivity analyses
on the cost of admission and efficacy of the thromboly-
tic resulted in minor variation in the baseline ICER.
We performed a probabilistic sensitivity analysis (PSA)
on the main variables of uncertainty, including the sen-
sitivity and specificity, the efficacy of thrombolytics in
India, the cost of ECGs in India. The PSA using the
variables in Table 3 resulted in a mean ICER of $154/
QALY (95% confidence interval, -$1790/QALY., $1830/
QALY). Greater than 97.5% of the values were less than
a willingness to pay threshold of $3000.
Discussion and Conclusions
We modeled a cohort of urban Indian patients with
acute chest pain presenting to a general practitioner to
compare the lifelong cost-effectiveness of a GP perform-
ing an ECG versus not performing one. Our model
found that it cost only $12.65 to gain an additional qual-
ity adjusted life year for this cohort. The relatively cheap
Table 3 Results of one-way sensitivity analysis
Baseline Value Tested Range ICER*
($/QALY gained)
Input variables
Chest pain is caused by ACS 0.1 0.01 – 0.2 Cost-saving†–119
GP sensitivity with ECG 0.818 0.7 – 0.98 Cost-saving – 103
GP sensitivity without ECG 0.667 0.667 – 0.818 13 – cost-saving
GP specificity with ECG 0.5 0.44 – 0.67 76 – cost-saving
GP specificity without ECG 0.3 0.3 – 0.5 57 – 351
Relative risk reduction of thrombolytics 0.750 0.71 – 0.875 13 – 12
Costs (2007 US$)
ECG 1.85 1.00 – 15.00 Cost-saving – 1124
Streptokinase 117.00 68.74 – 162.38 Cost-saving – 33
Admission 157.55 99.71 – 459.39 Cost-saving – 73
* The ICER is a comparison of the GP with ECG compared to GP without an ECG, with the value on the left corresponding with the leftward most value in the
tested range. All ICERs are rounded to the nearest dollar.
†“ Cost-saving” here is defined as the ECG intervention costing less and increasing QALYs gained compared to no ECG.
ACS = acute coronary syndrome, ECG = electrocardiogram, ICER = incremental cost-effectiveness ratio, QALY = quality adjusted life year
Figure 2 Tornado diagram. This Tornado diagram shows the incremental cost-effectiveness ratio (ICER) of the range of values for each variable
tested in the one-way sensitivity analysis. A negative ICER is described in the text as “cost-saving.”
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GP’s decision in the early and appropriate referral of
STEMI to a hospital where thrombolysis is adminis-
tered, as well as a reduction in unnecessary referrals of
patients without ACS to hospitals in order to “rule-out”
an event. One-way sensitivity analyses around uncertain
variables and assumptions demonstrated that this find-
ing is robust, especially for the values most commonly
found in contemporary Indian settings.
WHO considers interventions to be cost-effective if
they have ICERs that are less than three times gross
national income (GNI) per head [47]. In 2006, India’s
GNI per capita was $820, or $2460 after adjustment for
purchasing power parity [48]. As the baseline findings of
our model and all sensitivity analyses suggest the ICER
of the GP’s performing an ECG compared to not per-
forming one is under $1200, the ECG strategy is cer-
tainly cost-effective under current WHO definitions.
Furthermore, the results of the probabilistic sensitivity
analyses suggest the findings are robust with a 95% con-
fidence interval that is well below the likely willingness
to pay threshold for India based on WHO recommenda-
tions. Also, since we did not model the direct costs of
missed work owing to unnecessary hospitalization of
chest pain patients without ACS, it is likely that the
ECG strategy is even more cost-effective than our
results indicate.
Current guidelines recommend that all patients with
acute chest pain should be educated to directly present
to a hospital emergency department, and that any such
patients presenting to an outpatient practitioner should
be urgently referred [4]. We did not model a direct pre-
sentation strategy in this study owing to inadequate
data, though we think it would be interesting to com-
pare its cost-effectiveness to pre-hospital GP strategies
in the future. While such a direct presentation strategy
is likely to further increase the population eligible for
thrombolysis, it may also cost substantially more owing
to increased chest pain patients without ACS presenting
to crowded emergency rooms. Still, in the absence of
further evidence, we emphasize that direct presentation
with acute chest pain is preferable.
In the meantime, while the Indian public undergoes
public education regarding the association of chest pain
with serious conditions such as myocardial ischemia and
the possibility of myocardial infarction and the need to
present to an appropriate facility in a timely fashion; the
use of ECG machines by general practitioners may facil-
itate a timely presentation to an appropriate hospital
where acute treatments such as thrombolytics can be
applied. Training to use the ECG machine and interpret
results can be obtained for as little as $10 and machines
can be purchased for under $300. Many private based
GPs already may have them. Government based clinics
could consider their purchase if not already available.
T h ep o l i c yo fu s i n gE C Gm a c h i n e sm a yn o tb ef e a s i b l e
in rural areas however, given the access to facilities
where thrombolysis can be safely be administered may
not available.
We did not model a strategy whereby a GP would use
a point-of-care troponin assay to make a referral deci-
sion. Troponins are frequently negative early in ACS [4]
and it is unclear how useful a pre-hospital troponin
assay would be when compared to or combined with an
ECG. A pre-hospital troponin test’s impact on mortality
is also uncertain, as troponin assays mostly increase the
sensitivity for NSTE-ACS [49], for which thrombolytics
are not indicated. We think this is an area that deserves
additional research
Sensitivity analyses around the “sensitivity” and “specifi-
city” of the GP’s referral decisions with and without the
ECG robustly support our baseline findings. We per-
formed these analyses using an especially broad range of
possible values for two reasons. First, most data regarding
physicians’ performance in the diagnosis and referral of
ACS patients using ECG are from emergency depart-
ments; it is unknown if outpatient GPs perform similarly.
Second, there is very limited knowledge about how real
physicians perform in the diagnosis and referral of patients
with ACS when there is no ECG available. Therefore, in
the sensitivity analysis of the GP’s referral decision without
the ECG, we extended the tested range of values up to the
baseline values for the GP with the ECG. This is a very
conservative assumption, for it is the equivalent of stating
that the ECG is not helpful in referral decision-making,
w h i c hi sa to d d sw i t hp u b l i s h e dg u i d e l i n e s[ 4 ] .E v e ns o ,
these one-way analyses did not greatly affect the calculated
cost-effectiveness of the ECG strategy
There are several limitations to our study. First, our
baseline estimates of the “sensitivity” of a GP’s referral
decision are based on supplementary observations of a
small single-center study that had of mainly urban mid-
dle-class patients with confirmed ACS [8]. No confi-
dence intervals were reported in that study. The primary
study itself was retrospective, and it was not designed to
evaluate a GP’s pre-hospital decision making. However,
t h e s ea r et h eo n l yI n d i a nd a t aa v a i l a b l es t u d y i n gas c e -
nario common to urban India. Sensitivity analysis using
a wide range of values derived from developed world
studies for the sensitivity of GP’s referral decision
demonstrates that our findings are robust.
Second, owing to limited data on the ultimate diagno-
sis of acute chest pain across different age groups in
India, we only modeled a cohort of sixty-year old
patients. We assumed that ACS was the cause of chest
pain in 10% of the cohort, which was the lower end of
the reported range in developed world studies [19-22].
However, sensitivity analysis supports our finding that
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reported range. We found that when ACS as a cause of
chest pain was less prevalent, as might be expected in
younger cohorts, the ECG strategy was actually cost-sav-
ing. When ACS was the cause of acute chest pain in
20% of the modeled cohort, which may be true in older
cohorts of patients, the ECG strategy still had an ICER
still well beneath the WHO threshold for cost-effective-
ness. Further, a previous study has shown that the use
of thrombolytics in the elderly led to an cost-effective-
ness ratio for those over the age of 75 what was double
of that for those under the age of 70[50] Given that
women present at a later age and over all with lower
prevalence this would tend to make the ratios in general
lower for women than men, especially since case-fatality
is higher for females.
Third, owing to limited Indian data, our model did
not study the hour-dependent differential effects of
thrombolytics on mortality. Major international studies
suggest that the subgroup receiving thrombolytics within
three hours of ACS onset benefits more than the sub-
groups receiving them from 3-6 and 6-12 hours after
onset [23,25]. Our model treated receiving thrombolytics
as a binary variable, and the risk reduction in mortality
was the average reported from a large international trial.
We predict that modeling thrombolytic administration
as a time-dynamic variable would lead to even greater
reductions in mortality, which would further favor the
ECG strategy. This is a topic that deserves further
research once Indian data are available.
A recent study in the United States suggests that pre-
hospital ECG performed by emergency medical services
increase the frequency and rapidity of reperfusion thera-
pies for patients with STEMI [10]. Given that many Indian
ACS patients present first to a GP and the current absence
of emergency systems, it is reasonable to study whether a
GP performing pre-hospital ECG could yield analogous
benefits. We modeled such a GP-based strategy and found
it to be robustly cost-effective compared to a GP not per-
forming an ECG for urban patients with acute chest pain.
This finding should be considered a strong rationale for
clinical trials. Meanwhile, our findings also suggest that it
is sensible for GPs in urban India to perform an ECG in
patients with acute chest pain until improvements to
India’s emergency medical services are put in place.
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